John Mascarenhas, Joseph Scandura, Vikas Gupta, Kazuya Shimoda, James McCloskey, Firas El Chaer, Prithviraj Bose, Raajit Rampal, Andrew Srisuwananukorn, Timothy Devos, Ruben Mesa, Professor Francesco Passamonti, Srinivas Tantravahi, David Ross, Lindsay Rein, Jean-Jacques Kiladjian, Takanori Teshima, Takuji Yamauchi, Noboru Asada, Anna Halpern, Tamanna Haque, Etienne Paubelle, Noriko Fukuhara, Pankit Vachhani, Michiko Ichii, Ronald Hoffman, Marcello Rotta, Michael Keng, Stefan Wickenhauser, Karen Ansaldo, Masataka Seki, Jinny Lee, Vincent Loksa, Zhonggai Li, Jason Foulks, Sujan Kabir, Jatin Shah, Claire Harrison. "Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis." Blood, 2025. doi:10.1182/blood-2025-482